232 related articles for article (PubMed ID: 14598945)
1. Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder.
Mermershtain W; Cohen AD; Lazarev I; Grunwald M; Ariad S
J Chemother; 2003 Oct; 15(5):510-1. PubMed ID: 14598945
[TBL] [Abstract][Full Text] [Related]
2. [Toxicity of intravesical gemcitabine in superficial bladder cancer treatment].
Beardo Villar P; Gamaza Martínez R; Gavira Moreno R
Farm Hosp; 2014 May; 38(3):249-51. PubMed ID: 24951911
[TBL] [Abstract][Full Text] [Related]
3. Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine.
Sommers KR; Kong KM; Bui DT; Fruehauf JP; Holcombe RF
Anticancer Drugs; 2003 Sep; 14(8):659-62. PubMed ID: 14501389
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder.
Campodonico F; Maffezzini M
Urology; 2005 Nov; 66(5):1141-2; author reply 1142. PubMed ID: 16286156
[No Abstract] [Full Text] [Related]
6. Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma.
Lin CJ; Lim KH; Cheng YC; Chen HH; Wu CJ
Med Oncol; 2007; 24(4):455-7. PubMed ID: 17917099
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancer.
Borut K; Lijana ZK
Radiother Oncol; 2012 Mar; 102(3):412-5. PubMed ID: 21890225
[TBL] [Abstract][Full Text] [Related]
8. [Gemcitabine in advanced bladder cancer].
Lehmann J; Retz M; Lippert C; Albers P; Stöckle M
Urologe A; 2003 Jan; 42(1):63-77. PubMed ID: 12574885
[TBL] [Abstract][Full Text] [Related]
9. Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment.
Badger J; Kang S; Uzieblo A; Srinivas S
J Clin Oncol; 2005 Oct; 23(28):7224-5. PubMed ID: 16192608
[No Abstract] [Full Text] [Related]
10. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
Galsky MD; Hahn NM; Powles T; Hellerstedt BA; Lerner SP; Gardner TA; Yu M; O'Rourke M; Vogelzang NJ; Kocs D; McKenney SA; Melnyk AM; Hutson TE; Rauch M; Wang Y; Asmar L; Sonpavde G
Clin Genitourin Cancer; 2013 Jun; 11(2):175-81. PubMed ID: 23228446
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder.
Birlik M; Akar S; Tuzel E; Onen F; Ozer E; Manisali M; Kirkali Z; Akkoc N
J Cancer Res Clin Oncol; 2004 Feb; 130(2):122-5. PubMed ID: 14745551
[TBL] [Abstract][Full Text] [Related]
12. PHARMAC's response on gemcitabine and transparency.
Crausaz S; Metcalfe S
N Z Med J; 2005 Nov; 118(1225):U1741. PubMed ID: 16286949
[No Abstract] [Full Text] [Related]
13. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
Stadler WM; Kuzel T; Roth B; Raghavan D; Dorr FA
J Clin Oncol; 1997 Nov; 15(11):3394-8. PubMed ID: 9363871
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival under maintenance gemcitabine chemotherapy for metastatic transitional cell carcinoma.
Lehmann J; Retz M; Siemer S; Schreier U; Zwergel U; Stöckle M
Int J Urol; 2006 Jul; 13(7):1035-6. PubMed ID: 16882086
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
Serretta V; Galuffo A; Pavone C; Allegro R; Pavone-MacAluso M
Urology; 2005 Jan; 65(1):65-9. PubMed ID: 15667865
[TBL] [Abstract][Full Text] [Related]
17. Widespread Skin Necrosis Secondary to Gemcitabine Therapy.
Zito PM; Gonzalez AM; Fox JD; Cronin M; Mackrides N; Kirsner RS; Nichols AJ
J Drugs Dermatol; 2018 May; 17(5):582-585. PubMed ID: 29742194
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
Bellmunt J; Albiol S; de Olano AR; Pujadas J; Maroto P;
Ann Oncol; 2006 May; 17 Suppl 5():v113-7. PubMed ID: 16807437
[TBL] [Abstract][Full Text] [Related]
19. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a Phase II Hoosier Oncology Group Study.
Montie JE
J Urol; 2005 Nov; 174(5):1784. PubMed ID: 16217286
[No Abstract] [Full Text] [Related]
20. Capecitabine: toxic epidermal necrolysis and Stevens-Johnson syndrome.
Prescrire Int; 2014 Jun; 23(150):157. PubMed ID: 25121151
[No Abstract] [Full Text] [Related]
[Next] [New Search]
